Tesla rumored to be taking over this small lithium mining company

These setups look primed                                                                                                                                                                                                                                                                                                                                                                                                                 February 21, 2023 | [Read Online]( *Together with Good day, 360 – Here are our top 3 trade ideas today – these setups look primed! Be the best prepared trader on the Street! SGML - Up 27% as Tesla said to be considering buying this small lithium miner, reports Bloomberg TRKA - This MEME stock is up over 40% on no news ATNM - 10% higher in pre-market after positive leukemia drug results *A message from Capital Gains It’s the gym, for your finance brain. 5-minutes per day is great, but like it or not, real gains come after putting in hours for years. [Capital Gains]( is an educational newsletter spun out of The Diff: a deeply analytical newsletter that applies concepts in finance, economics, and corporate strategy. The problem is that those concepts aren’t taught in school, so the analysis tends to appeal to founders, VCs, hedge fund managers, and the like. Whether you’re on a finance career track, trying to understand what your company’s stock options package means, or just curious about how the economy works, Capital Gains gives you the mental models you need. [Subscribe here]( for the free weekly email! *Sponsored content. Please see disclosures below. SGML - Up 27% as Tesla said to be considering buying this small lithium miner, reports Bloomberg On Friday in after-hours trade, Bloomberg reported (citing sources) that Tesla is considering buying Sigma Lithium Corp (SGML) causing the stock to trade over 25% in pre-market this morning. Elon Musk has been talking about Tesla mining its own lithium for numerous years now so this report may well have some legs. The potential deal is still just a rumor at this point. The pre-market high for SGML is $39.99 and represents an all-time high for SGML. A takeover offer would likely be above all-time highs given that SGML has been one of the stronger stocks in the market over the last 12 months and thus any takeover should be at a significant premium. $37 has so far been a pivot point in the pre-market. Above it targets to the upside are $38, $39 and $40. Below it, there is potential support at $36, $35.33 and a gap to fill all the way to $29.48 if these rumors fail to have substance or the deal falls through. TRKA - This MEME stock is up over 40% on no news Troika Media Group (TRKA) had no news but was one of the top Reddit short squeeze mentions on Friday. With a short float of just under 20% according to Finviz, TRKA is a MEME favorite. The stock is down over 80% from its 2021 IPO price and is currently a penny stock. The Apes finally got a hold of this one so it is one to keep on your watchlist today especially if some stubborn shorts get trapped. $0.39 was resistance in the pre-market and TRKA also failed there in the after-hours a couple of weeks back so that is the first major target for bulls. Above $0.39, there is potential resistance at $0.45 and $0.50, with a gap to fill at $0.65. The $0.30 area has acted as support in the pre-market so far and below that there is a gap to fill at $0.2201. ATNM - 10% higher in pre-market after positive leukemia drug results On Sunday, Actinium Pharmaceuticals (ATNM) announced positive full data results from its Phase 3 trial in patients with active, relapsed or refractory acute myeloid leukemia. The stock was up as high as 30% post the news this morning and is now around 10% higher. In addition, HC Wainwright reiterated its Buy rating on ATNM and maintained its $53 price target representing over 200% upside from current levels. There has been some support for ATNM in the pre-market at the $15 area so that should be an important pivot level this morning. The $15 area was a major resistance level from back in November. Above it, targets to the upside are $17, and then the pre-market high of $18 with $19 and $20 above that. Below $15, there is a gap to fill at $13.76 with potential support at $12 and then $11 below that. Economic Calendar (EST) 9:45am PMI Composite 10:00am Existing Home Sales No Fed Speakers Scheduled Earnings for Today (After Market) ABCL, AGR, AHT, AINV, ALIT, APLE, AROC, ATRC, BCC, BKD, BSM, BXC, CHK, COIN, CSGP, CSR, CVI, CW, CWAN, CWH, CZR, EQX, ESI, EXAS, FANG, FLS, GFL, GMED, GTE, HALO, HCKT, HY, IAA, ICCC, IOSP, IVR, JBGS, KAR, KEYS, KW, LAND, LEU, LPI, LZB, MATX, MED, MTDR, NHI, O, PANW, PEB, PET, PSA, PTCT, PUMP, QTWO, QUAD, RBA, RIG, SAND, SBAC, SBRA, SKT, SPT, STAA, TALK, TOL, TWNK, UAN, UNVR, VLRS, VNOM, VRE, WK, WSC, WTTR, XPER, ZIP Top Headlines HLX: Helix Announces $200 Million Share Repurchase Program MNOV: MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics RNAZ: Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules TSLA: US NHTSA Reaches Out To Tesla About Fatal Crash In California - Driver Died After Colliding With Fire Truck In Bay Area : Tesla driver killed after barreling into ladder truck blocking accident scene on California freeway -- California Highway Patrol officials did not immediately known if the driver was impaired or if the car was in Autopilot mode -- Fox UBER: announced a partnership with Tata Motors to bring 25,000 new EVs onto Uber’s platform in India LXRX: New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology AMZN: Amazon Corporate Workers Face Pay Reduction After Shares Slip – WSJ TSLA: Tesla is poised to unveil a cheaper ‘Model 2’ as other manufacturers struggle to turn a profit from the electric vehicle revolution -- The Times UK HUGE: FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum MYNZ: Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program AFMD: AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target META: Tencent in Talks to Sell Meta’s Quest 2 VR Headset in China The deal could be a boon for Meta in China, where Facebook has been blocked since 2009 WSJ NIO: China's Nio to build factory for budget EVs – Reuters CRNT: Ceragon Launches AI-Based Intelligence and Management Software Suite for Multi-Vendor Wireless Transport Networks VALN: FDA Accepts Valneva’s Chikungunya Vaccine BLA for Priority Review. PDUFA end of August GOOG: U.S. Supreme Court mulls challenge to internet firms' legal shield TECK: announces $250M share repurchase plan TECK: Teck Resources to separate into two publicly-listed companies MAXR: to provide environmental monitoring for Government of Guyana AULT: Ault Alliance Announces the Addition of Data Center Services Veteran, Jay Looney, as the Chief Executive Officer of its Wholly-Owned Subsidiary, AC Management, Inc. AKBA: Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease CNTG: In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD) MRK: Phase 3 move-ahead Trial Evaluating LAGEVRIO (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19 MRK: Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline PFE: U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review NETI: Eneti Inc. Announces A Contract Award for Seajacks BDX: BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test FWBI: First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference EVOK: Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session CGC: CANOPY GROWTH ANNOUNCES US$150 MILLION REGISTERED DIRECT OFFERING DPRO: Draganfly to Showcase its Drone and AI Technology at the World Police Summit in Dubai To Your Success! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions DISCLAIMER: To more fully understand RagingBull.com, LLC’s issuer-paid advertisement disclaimer and disclosure policy located at [(. *ISSUER-PAID ADVERTISEMENT. RagingBull expects to receive about $1000 for this ad. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Raging Bull nor any of its owners, employees OR INDEPENDENT CONTRACTORS is CURRENTLY registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements.In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 lee, NH 03861, United States [Publish on Beehiiv](